We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current ZYME market cap is 443.44M. The company's latest EPS is USD -1.7791 and P/E is -3.61.
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 17.22M | 10.03M | 19.24M | 16M | 31.03M |
| Operating Income | -9.17M | -37.8M | -42.89M | -16.92M | -14.71M |
| Net Income | -14.48M | -31.65M | -37.69M | -29.85M | -23.51M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 38.95M | 26.68M | 412.48M | 76.3M | 76.3M |
| Operating Income | -187.47M | -215.63M | 130.53M | -137.76M | -119.82M |
| Net Income | -180.55M | -211.84M | 124.34M | -118.67M | -122.7M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 580.88M | 553.75M | 515.63M | 487.15M | 463.09M |
| Total Liabilities | 116.07M | 115.75M | 109.47M | 120.17M | 124.32M |
| Total Equity | 464.81M | 438M | 406.16M | 366.98M | 338.77M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 538.38M | 389.13M | 648.73M | 580.88M | 463.09M |
| Total Liabilities | 128.45M | 140.04M | 155.77M | 116.07M | 124.32M |
| Total Equity | 409.92M | 249.09M | 492.96M | 464.81M | 338.77M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -118.3M | -37.67M | -62.66M | -68.54M | -110.04M |
| Investing | -207.25M | -7.32M | -27.29M | 44.97M | 38.76M |
| Financing | 81.85M | 2.12M | 3.17M | -11.81M | -20.45M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -151.4M | -192.45M | 144.11M | -118.3M | -110.04M |
| Investing | -43.44M | 144.6M | -53.85M | -207.25M | 38.76M |
| Financing | 308.98M | 8.01M | 108.58M | 81.85M | -20.45M |
| Market Cap | 443.44M |
| Price to Earnings Ratio | -3.61 |
| Price to Sales Ratio | 5.81 |
| Price to Cash Ratio | 6.71 |
| Price to Book Ratio | 1.31 |
| Dividend Yield | - |
| Shares Outstanding | 68.96M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.4 (5.97%) |
| Company Name | Zymeworks Inc |
| Address |
595 burrard street north vancouver, british columbia V7X 1L3 |
| Website | https://www.zymeworks.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
